Navigation Links
Lorus initiates development program exploring novel route of administration for LOR-2040
Date:4/22/2008

cally confined, superficial bladder tumors. In fact intravesical administration exposes the bladder tumor to higher levels of drugs that may prevent tumor cells from becoming invasive and spreading (metastasizing) to other organs. This treatment method is a standard regimen used for many approved chemotherapy drugs to treat superficial bladder cancer.

"I am pleased that we have initiated the studies that explore a novel way of administering LOR-2040 directly to bladder tumors and that we are on schedule to advance LOR-2040 in this indication", said Dr. Aiping Young, President and CEO of Lorus. "Bladder cancer is seventh most common cancer worldwide and is a significant target indication for new therapeutics. Coupled with the high risk of recurrence, even in patients with early stage disease, adding a non-systemic treatment to the currently available treatment options has significant potential."

About LOR-2040

LOR-2040 (formerly GTI-2040) is an RNA-targeted drug candidate specific for the R2 subunit of ribonucleotide reductase, which is required for DNA synthesis and cell proliferation. LOR-2040 has demonstrated strong antitumor and antimetastatic activity in a variety of tumor types in both in vivo and in vitro models. LOR-2040 is under study in a multiple Phase I/II clinical program, including an advanced Phase II clinical trial with LOR-2040 and high dose Ara-C (HiDAC) in refractory and relapsed Acute Myeloid Leukemia (AML). The R2 target has been described as a malignant determinant that is elevated in a wide range of tumors, which can cooperate with a variety of cellular cancer causing genes known as oncogenes to enhance tumor growth and metastatic potential.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of novel therapeutics for the treatment of cancer that are at various stages of development spanning discovery to clinical trials. Lorus' goal is to capitalize on its research, preclin
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
2. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
3. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
4. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
5. SemBioSys initiates toxicology study for safflower-produced insulin
6. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
7. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
8. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
9. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
10. Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology
11. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 CURE™ magazine will ... December 5, 2014, in San Francisco prior to the ... event will honor clinicians, caregivers, and advocates who have ... (MPNs). , Special guest speaker Charles Esten, from ... journey at the reception. Over a decade ago, ...
(Date:11/26/2014)... N.J. , Nov. 25, 2014  Roka Bioscience, Inc. ... on providing advanced testing solutions for the detection of foodborne ... present at the Piper Jaffray  26 th Annual Healthcare ... will be held at The New York Palace in ... this presentation, material information concerning the Company, its operations, strategies ...
(Date:11/24/2014)...   First published articles now ... Elsevier , a world-leading provider of scientific, technical and medical ... of the latest title in the Current Opinion journal ... . Current Opinion in ... to keep up-to-date with the expanding volume of information published ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 The ... ” from METTLER TOLEDO demonstrates how to reduce ... Power analytics and sample panel design can be ... chemistry and protect against corrosion and deposition. Dedicated ... a significant amount of panel space. Additionally, installing ...
Breaking Biology Technology:CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 3New Video Shows How to Simplify Cycle Chemistry Sample Panels to Save Time and Costs 2
... PolyOne Corporation,(NYSE: POL ), a premier ... today that it has entered into an exclusive,license ... owned by Battelle., The global market for ... all production consumed in vinyl-based formulations.,Specialty plasticizers currently ...
... 107% over Second Quarter 2007, EMERYVILLE, Calif., Aug. ... reported its financial results,for the three and six months ... million, or $0.08 per diluted share, for the second ... million, or $0.22 per diluted share, in the,same period ...
... /PRNewswire-FirstCall/ - Atrium Innovations Inc.,(TSX: ATB), a recognized ... endorsed products for the health and,nutrition industries, today ... Pierre Fitzgibbon, will present a company overview,at the ... on,Tuesday, August 12, 2008 at 11 am (eastern ...
Cached Biology Technology:PolyOne Corporation Announces an Exclusive License Agreement with Battelle for Bio-Plasticizer Technology 2Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 2Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 3Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 4Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 5Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 6Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 7Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 8Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 9Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 10
(Date:11/18/2014)...  The Secure Identity & Biometrics Association (SIBA) ... the formation of The Airport Entry and Exit ... and Biometric Entry and Exit Solutions Framework for ... from BORDERPOL, the international non-profit organization that works ... regarding border security, traveler and migration systems. ...
(Date:11/18/2014)... -- The Parenteral Drug Association (PDA) today confirmed that seven ... at least seven more will participate in the upcoming 2014 ... in Washington D.C. , Dec. 2-4. ... from the regulatory agencies in the United States ... effort to help advance the use of metrics in the ...
(Date:11/15/2014)... , Nov. 13, 2014  While we may still be ... McCoy used in "Star Trek" to gain instant access to ... to work with smartphones and tablets for monitoring and measuring ... healthcare world. This may seem a tad Orwellian to some, ... adopt some of these technological opportunities into their healthcare regime. ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... but many dinosaurs apparently had genomes no larger than that ... bone cell and genome size among living species and then ... 31 species of extinct dinosaurs and birds, whose bone cells ... researchers, at Harvard University and the University of Reading, were ...
... such as Unreal Tournament, can actually improve your vision. ... people who played action video games for a few hours ... about 20 percent in their ability to identify letters presented ... regular ophthalmology clinics. , In essence, playing video game ...
... Pennsylvania School of Medicine & School of Engineering and ... drugs to tumors. By using a cylindrical-shaped carrier they ... to an animal model of lung cancer ten times ... have implications for drug delivery as well as for ...
Cached Biology News:Despite their heft, many dinosaurs had surprisingly tiny genomes 2Action video games sharpen vision 20 percent 2Penn researchers show how nanocylinders deliver medicine better than nanospheres 2
... Features Convenient platform for tube handling and ... x 0.2ml V-bottom tubes - 96 ... - Thermo-Fast® 96 Non-Skirted Plate ... - 48 x 0.5ml Thermo-Tubes Multiple workstations can ...
... upgrade for Shimadzu Phoretix 2D, Expression and ... tools for comparative gel analysis studies in ... base add on component Oracle ... 9i release 2 client software). ...
... HISTAR detection systems provide linking and ... with species specific primary antibodies for ... Visualisation is accomplished using an ultra-sensitive ... polymer labelling technology. Secondary antibodies are ...
... concentration - 5 units/µL ,• High specific ... ,• Leaves an 'A' overhang ,• Processes ... exhibits very high activity in primer extension ... the quality of the enzyme, each lot ...
Biology Products: